Drug
TRK 820 clinical trials
Also written Nalfurafine Hydrochloride and Remitch®.
- studies test it
- 11
- open now
- 3
- in phase 3
- 3
- first study started
- 2008
Keep track of what changes. Save the TRK 820 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Other names
Studies by the year they started
11 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2008 | 3 |
| 2009 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 2
- Phase 3
- 3
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 3
Toray Industries, Inc (3) · SK Chemicals Co., Ltd. (2) · Shandong New Time Pharmaceutical Co., LTD (1) · Indonesia University (1) · Chinese PLA General Hospital (1) · Guangdong Provincial People's Hospital (1) · Shenyang Sunshine Pharmaceutical Co., LTD. (1) · Acologix, Inc. (1)
Studies
Open first, then newest update. How each study uses TRK 820 is read from its arms, and is right about nine times in ten.
Testing it · 11
- Efficacy and Safety of Nalfurafine Hydrochloride ODT for Moderate-to-Severe Pruritus in Patients on Peritoneal DialysisRecruitingNot applicableGuangdong Provincial People's HospitalNCT07098351Written as Remitch
- Efficacy of Nalfurafine for Chronic Kidney Disease-Associated Pruritus in Twice-Weekly Hemodialysis Patients: A Randomized Controlled TrialNot yet recruitingPhase 4Indonesia UniversityNCT07769073Written as Nalfurafine Hydrochloride
- Clinical Study on the Efficacy and Safety of Nalfurafine Hydrochloride Orally Disintegrating Tablets in Treating Pruritus in Patients Undergoing Maintenance HemodialysisNot yet recruitingNot applicableChinese PLA General HospitalNCT07650851Written as Nalfurafine Hydrochloride
- Bioequivalence Study of Nalfurafine Hydrochloride Orally Disintegrating Tablets on Fasting and Fed in HumansCompletedNot applicableShandong New Time Pharmaceutical Co., LTDNCT07478133Written as Remitch®
- Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving HemodialysisTerminatedPhase 2Toray Industries, IncNCT01660243Written as Nalfurafine hydrochloride(MT-9938) 2.5μg
- A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating TabletStatus unknownPhase 3Shenyang Sunshine Pharmaceutical Co., LTD.NCT04728984Written as Nalfurafine Hydrochloride
- TRK-820 Study in Subjects on Hemodialysis With or Without Uremic PruritusCompletedPhase 1Toray Industries, IncNCT03002233Written as TRK-820
- Efficacy and Safety Study of TRK-820 to Treat Conventional-treatment-resistant Pruritus in Patients Receiving HemodialysisCompletedPhase 3SK Chemicals Co., Ltd.NCT01513161Written as nalfurafine hydrochloride (TRK-820)
- Safety Study of TRK-820 for Patient With HemodialysisCompletedPhase 1SK Chemicals Co., Ltd.NCT01248650Written as nalfurafine hydrochloride
- A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch)Status unknownPhase 3Acologix, Inc.NCT00793156Written as Nalfurafine HCl 2.5 µg
- Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -CompletedPhase 2Toray Industries, IncNCT00638495Written as Nalfurafine Hydrochloride (TRK-820)
As the comparator · 1 — what is tested is compared with TRK 820
Codes
What other systems call TRK 820 · ClinicalTrials.gg INT004055
- MeSH (NLM) C111212TRK 820Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) 25CC4N0P8JNALFURAFINE HYDROCHLORIDEConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C111212 | TRK 820 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 25CC4N0P8J | NALFURAFINE HYDROCHLORIDE | Confirmed FDA, NLM |
Also registered as nalfurafine (UNII XC41AVD567).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.